Reduced Capacity of Neonatal Lymphocytes to Inhibit the Growth of &lt;i&gt;Candida albicans&lt;/i&gt;

Shareef, Maliha; Myers, Thomas F.; Mathews, Herbert L.; Witek-Janusek, Linda

doi:10.1159/000014074

Cited by 11 publications

(4 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“….0001 P ! .01 most immature and LBW infants, which confirms and extends our earlier observations [11]. Furthermore, the present study provides the first evidence to indicate that the observed reduction in infant antifungal capacity is due, in part, to an impaired ability of lymphocytes to adhere to C. albicans.…”

Section: Discussionsupporting

confidence: 91%

Reduced Lymphocyte‐Mediated Antifungal Capacity in High‐Risk Infants

2002

View full text Add to dashboard Cite

Premature and critically ill infants are highly susceptible to Candida albicans. This study evaluated the lymphocyte-mediated antifungal capacity of infants relative to birth weight, prematurity, and illness severity. Growth inhibition of C. albicans by lymphocytes from preterm and low-birth weight infants was significantly reduced, compared with full-term and normal-weight infants. Lymphocyte growth inhibition of C. albicans is dependent on cell adhesion to the fungus. Compared with full-term infants, lymphocytes from preterm infants had a reduced capacity to adhere to C. albicans. Furthermore, infants with greater severity of illness (score for neonatal acute physiology [SNAP], >or=10) exhibited significantly reduced lymphocyte-mediated antifungal capacity and fungal adhesion. Although gestational age, birth weight, and SNAP were significantly associated with lymphocyte-mediated growth inhibition and adhesion, stepwise regression analysis demonstrated that gestational age best predicted both lymphocyte growth inhibition of and adhesion to the fungus.

show abstract

Section: Discussionsupporting

confidence: 91%

Reduced Lymphocyte‐Mediated Antifungal Capacity in High‐Risk Infants

2002

View full text Add to dashboard Cite

show abstract

“…In agreement with other studies reporting an increased incidence of systemic Candida infection in VLBW infants (between 2 and 5%), [5][6][7][15][16][17][18][19] in our study, the rate of candidemia (3.3%) increased 33-fold and the rate of urinary tract infection (1.2%) increased 17-fold in infants weighing Յ 1500 in comparison with the cohort of infants weighing > 1500 g. These differences may be explained by their immature host defenses, frequent exposure to invasive diagnostic and therapeutic procedures, and prolonged hospital stay. 1,2,17,[20][21][22] Risk factors frequently involved in Candida infections, [23][24][25][26][27][28][29] such as use of broad-spectrum antimicrobials, steroid therapy, central vascular catheters, parenteral nutrition, intralipid infusions, prolonged endotracheal intubation, and complex surgical procedures especially in infants at term were also found in our study.…”

Section: Discussionmentioning

confidence: 53%

Neonatal Invasive Candidiasis: A Prospective Multicenter Study of 118 Cases

Sastre

Cotallo²,

Colomer³

et al. 2003

Am J Perinatol

102

View full text Add to dashboard Cite

A prospective multicenter study was conducted to assess the epidemiology of neonatal invasive candidiasis in Spain. In a total of 20,565 admissions to the 27 participating neonatal units over an 18-month period, systemic candidiasis was diagnosed in 118 (0.57%) neonates. Candida species were isolated from the blood in 79 infants, from the urine in 33, and from the cerebrospinal fluid in 4; in 2 cases, histologic evidence of deep tissue candidiasis was found at autopsy. Very-low-birth-weight (VLBW) infants (< or = 1500 g) showed a significantly higher incidence of systemic candidiasis (4.8%) than infants weighing > 1500 g (0.2%) ( p < 0.001). Candida albicans was the most frequent species (52.5%) followed by C. parapsilosis (23.7%), and C. tropicalis (7.6%). Only seven infants were treated with amphotericin B (initial dose 0.18 +/- 0.3 mg/kg, maximal daily dose 1.7 +/- 0.9 mg/kg) but treatment was stopped in three of them (43%) due to nephrotoxicity. Liposomal amphotericin B was given to 81 neonates and amphotericin B lipid complex to 29. There were no differences in mortality rate and in the incidence of adverse effects in relation to treatment with liposomal amphotericin B or amphotericin B lipid complex. The mortality rate was 10.2% and all deaths occurred in the VLBW cohort with candidemia.

show abstract

“…Fetal T cell function has been noted by the midsecond trimester. Consistent with this finding, Shareef et al [51] noted that lymphocytes from cord blood of infants delivered prior to 32 weeks gestation showed a marked reduction in growth inhibition capacity for C. albicans compared to infants delivered after 32 weeks of gestation. Therefore the association of the IUCD and fetal candidiasis may involve the introduction of Candida into the amniotic cavity prior to onset adequate fetal immunocompetency.…”

Section: Discussionmentioning

confidence: 65%

Intra amniotic candidiasis. Case report and meta-analysis of 54 cases

Roqué

Abdelhak²,

Young³

1999

Journal of Perinatal Medicine

View full text Add to dashboard Cite

We present a case of mid pregnancy loss with retained intrauterine contraceptive device associated with fetal Candida infection. Review of English literature identified 53 additional cases of fetal candidal infection, with 17 associated with an IUCD in situ. The presence of an IUCD was associated with delivery at a statistically significant earlier gestational age when compared to cases not associated with an IUCD (23.3 +/- 4.9 vs 31.6 +/- 7.0, p < 0.001). Seventy-seven percent of fetal candidal infections associated with an IUCD were systemic (heart, brain, liver, gastrointestinal, lung) compared to 33% of cases not associated with an IUCD. In contrast to bacterial intraamniotic infections there was a low incidence of maternal febrile morbidity. An hypothesis as to the pathogenesis of Candidal infections in the presence and absence of an IUCD is offered as well as a paradigm for the management of the gravid patient with an IUCD in situ.

show abstract

Reduced Capacity of Neonatal Lymphocytes to Inhibit the Growth of <i>Candida albicans</i>

Cited by 11 publications

References 32 publications

Reduced Lymphocyte‐Mediated Antifungal Capacity in High‐Risk Infants

Reduced Lymphocyte‐Mediated Antifungal Capacity in High‐Risk Infants

Neonatal Invasive Candidiasis: A Prospective Multicenter Study of 118 Cases

Intra amniotic candidiasis. Case report and meta-analysis of 54 cases

Contact Info

Product

Resources

About